Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $9.3652W HIGH $26.18
Volume
603.27 K
Value Traded
6.65 M
Short % Float
2.5%
-9.48%Week
-28.94%1 Month
-42.09%3 Month
-53.62%6 Month
-69.5%5 Year
-92.16%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
600.48 M
EPS (TTM)
-2.80
P/E Ratio
-
Ent. Value
425.58 M
Total Shares
62.88 M
Float Shares
54.19 M
Insiders
13.78%
Institutions
40.72%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
DBVT Catalyst Timeline
Dated clinical, regulatory and corporate events for DBV Technologies S.A.
Catalyst Timeline
Dated clinical, regulatory & corporate events for DBV Technologies S.A.
820Total events
10Upcoming
147Tier-1 (high impact)
2013 to 2027Coverage
Upcoming catalysts 2
Event history 50
●BLA SubmissionRegulatory Filing
DBV submits BLA to FDA for VIASKIN Peanut Patch in children 4-7 years
peanut allergy in children aged 4 through 7 yearssource ↗
◆Priority ReviewRegulatory Filing
DBV requests Priority Review of BLA for VIASKIN Peanut Patch
peanut allergy in children aged 4 through 7 yearssource ↗
●Priority Review DesignationDesignation
DBV requests Priority Review of BLA for VIASKIN Peanut Patch
peanut allergy in children aged 4 through 7 yearssource ↗
◆Timing GuidancePresentation
BLA submission anticipated in Q3 2026
peanut allergy in children aged 4 through 7 yearssource ↗
◆NDA SubmissionRegulatory Filing
BLA submission for Viaskin peanut patch in 1-3-year-olds
peanut allergy in 1-3-year-oldssource ↗
▲FDA Feedback ReceivedFDA Meeting
FDA provided actionable input on CMC and biostatistical elements; no additional data requested
peanut allergy in children aged 4 through 7 yearssource ↗
◆Oral PresentationPresentation
Presentation of THRIVE study design at EAACI 2026
peanut allergysource ↗
◆Oral PresentationPresentation
Presentation of VITESSE subgroup analysis at EAACI 2026
peanut allergysource ↗
◆Oral PresentationPresentation
Fireside chat at Goldman Sachs 47th Annual Global Healthcare Conference
▲Subgroup AnalysisClinical Data
Positive subgroup data from VITESSE in children with atopic comorbidities
peanut allergy with atopic comorbiditiessource ↗
▲First Patient DosedTrial
First participant screened in THRIVE Phase 2 study of VIASKIN Peanut Patch in infants 6-12 months
Peanut Allergysource ↗
◆Oral PresentationPresentation
DBV Technologies CEO fireside chat at H.C. Wainwright 4th Annual BioConnect Investor Conference
◆Enrollment UpdateTrial
Ongoing recruitment for COMFORT Toddlers study
peanut allergy in toddlers aged 1 to 3 yearssource ↗
◆Timing GuidancePresentation
Potential BLA filing for VIASKIN Peanut patch for toddlers ages 1-3 years
peanut allergysource ↗
●Timing GuidancePresentation
BLA submission anticipated under Accelerated Approval Pathway
peanut allergysource ↗
▲Enrollment CompleteTrial
Recruitment closed for COMFORT Toddlers supplemental safety study
peanut allergy in toddlers aged 1 through 3 yearssource ↗
●Quarterly UpdateCorporate
Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
▲Oral PresentationPresentation
Additional positive data from Phase 3 VITESSE study presented at AAAAI 2026 Annual Meeting
peanut allergysource ↗
◆Oral PresentationPresentation
Oral presentation of additional VITESSE Phase 3 data for VIASKIN Peanut Patch in children 4-7 years at AAAAI 2026
Peanut allergysource ↗
◆Oral PresentationPresentation
CEO Daniel Tassé fireside chat at Guggenheim Securities Emerging Outlook: Biotech Summit
▲Equity OfferingCorporate
Full exercise of ABSA Warrants and BS Warrants from March 2025 financing
▲Runway Guidance UpdateCorporate
Cash runway extended to at least 12 months including through anticipated launch
▲Runway Guidance UpdateCorporate
Company funded for at least 12 months including potential launch
◆BLA SubmissionRegulatory Filing
BLA submission for VIASKIN Peanut patch in 4-7-year-olds
peanut allergysource ↗
◆NDA SubmissionRegulatory Filing
BLA submission for Viaskin peanut patch in 4-7-year-olds
peanut allergy in 4-7-year-oldssource ↗
▲Topline ReadoutClinical Data
Positive VITESSE topline results in children 4-7 years old
peanut allergysource ↗
▲Topline ReadoutClinical Data
Positive VITESSE topline results announced
Peanut allergy in children aged 4-7 yearssource ↗
▲Primary Endpoint MetClinical Data
VITESSE Phase 3 trial met primary endpoint with statistical significance
peanut allergysource ↗
▲Topline ReadoutClinical Data
Positive topline results from Phase 3 VITESSE trial of VIASKIN Peanut patch in children aged 4-7 years
peanut allergysource ↗
▲Equity OfferingCorporate
Acceleration of warrant exercise period due to positive VITESSE results
▲Last Patient Last VisitTrial
Last patient last visit in Phase 3 VITESSE trial of VIASKIN Peanut in children aged 4-7
peanut allergy in children aged 4-7source ↗
◆Oral PresentationPresentation
DBV Technologies participates in Guggenheim Healthcare Innovation Conference fireside chat
Past FDA Catalysts and PDUFA Decisions
How DBVT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | VIASKIN® Peanut Patch | BLA Submission | BLA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C42 / 100
Pipeline Score
$289M
Pipeline Value
Overvalued
Valuation Signal
4
Drugs Scored
0.4x
rNPV / MCap
Top 33%
Micro Cap(rank 218 of 658)
Percentile Rank
DBV Technologies S.A. carries a moderate pipeline score (42/100), with $963M risk-adjusted pipeline value, led by DBV712 in Allergy (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DBV712 Small moleculeNCT05741476 | Peanut Allergy | Phase 3 | ACTIVE NOT_RECRUITING | 904 | Oct 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every DBVT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| VIASKIN Peanut Patch Accelerated | peanut allergy | Phase 3 | 2026-06-08 | asthma: viaskin patch 48.3%, placebo 19.6%, risk difference 28.8, confidence interval 15.79, 41.76; food allergies: viaskin patch 46.8%, placebo 13.6%, risk difference 33.2, confidence interval 23.50, 42.83; atopic dermatitis: viaskin patch 47.2%, placebo 13.2%, risk difference 34.0, confidence interval 25.09, 42.94Read More | DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Mohideen PharisOfficer (Chief Medical Officer) | Sell | -464 144,531 held | $2.70 | 07/29/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DBVT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BIOIMPACT CAPITAL LLC | 3.7 % (-56 %) | 60.13 M | 3.67 M | -29.68% ( -1.55 M) |
DBVT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DBVT ranks across every disease it competes in
Competitive Position is a premium feature
See how DBVT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDBVT News
DBVTDBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years
DBV Technologies has submitted a Biologics License Application (BLA) to the U.S. FDA for the VIASKIN® Peanut Patch aimed at children aged 4-7 with peanut allergies. This submission follows the successful Phase 3 VITESSE trial, which is the largest clinical trial for this demographic. DBV has also requested Priority Review from the FDA, highlighting the urgency of making this treatment available.
Read more →DBVTDBV Technologies to Participate in Upcoming September Investor Conferences
DBV Technologies has announced its participation in several investor conferences in September 2026, including the Cantor Global Healthcare Conference and Citi's Biopharma Back to School Conference. The company is focused on developing treatments for food allergies using its proprietary VIASKIN® patch technology. Live webcasts of the events will be available on their website.
Read more →DBVTDBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq
DBV Technologies has announced the sale of approximately $50 million in American Depositary Shares (ADSs) through its At-The-Market (ATM) Program. This capital increase, involving the issuance of 18,288,220 new Ordinary Shares, is set to enhance the company's financial resources. However, existing shareholders will experience a dilution of about 5.82%. The new shares will be available for trading on Nasdaq and Euronext Paris.
Read more →DBVTDBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales
DBV Technologies has filed a new shelf registration statement with the SEC for an at-the-market offering of up to $150 million in American Depositary Shares. The funds raised will primarily support manufacturing expansion and the development of its food allergy treatment, the VIASKIN Peanut Patch. The offering is part of the company's strategy to enhance its financial flexibility.
Read more →DBVTDBV Technologies dépose un prospectus relatif à son Programme At-The-Market (ATM) pour un montant pouvant atteindre 150 millions de dollars
DBV Technologies has announced the filing of a new automatic registration statement with the SEC for its At-The-Market (ATM) program, allowing for the sale of American Depositary Shares (ADSs) up to $150 million. This program aims to finance the expansion of manufacturing capabilities and the development of its product VIASKIN® Peanut for children. The registration statement became effective upon filing, enabling the company to proceed with its financing activities.
Read more →DBVTDBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report
DBV Technologies has announced the filing of its 2026 Half-Year Report with the French market authority. The report is available for consultation on the company's website and the AMF website. DBV Technologies is dedicated to developing treatments for food allergies using its proprietary VIASKIN technology, which aims to modify immune responses to allergens.
Read more →DBVTDBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update
DBV Technologies reported its financial results for Q2 and H1 2026, highlighting progress in its BLA submission for the VIASKIN® Peanut Patch aimed at children aged 4-7. The company has engaged positively with the FDA and anticipates submitting the BLA in Q3 2026. Despite a net loss of $98 million, DBV maintains a strong cash position to support operations into 2027.
Read more →DBVTDBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026
DBV Technologies will host a conference call on July 16, 2026, to discuss its second quarter financial results and provide a business update. The call will be accessible via teleconference and a live audio webcast. The company is dedicated to developing treatments for food allergies using its proprietary VIASKIN®Patch technology.
Read more →DBVT▲ +11.1%on this news
Bilan semestriel du Contrat de Liquidité de DBV Technologies avec ODDO BHF
DBV Technologies has released its semi-annual report on its liquidity contract with ODDO BHF. The report highlights an increase in liquidity holdings, with 146,321 shares and €396,088.22 as of June 30, 2026. The company executed 1,989 buy transactions and 2,012 sell transactions during the first half of 2026, indicating active trading.
Read more →DBVT▲ +11.1%on this news
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBV Technologies released its Half-Year Report on the liquidity contract with ODDO BHF, showing a significant increase in shares held in the liquidity account. As of June 30, 2026, the account held 146,321 shares and €396,088.22. The report details trading activities, including 1,989 buy and 2,012 sales transactions, indicating active market participation.
Read more →DBVTDBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing
DBV Technologies has provided an update on its Biologics License Application (BLA) for the VIASKIN® Peanut Patch aimed at children aged 4 to 7. The company is working closely with the FDA to ensure a comprehensive review process and expects to submit the BLA in the third quarter of 2026. The FDA has not requested additional data, indicating a positive collaboration.
Read more →DBVTDBV Technologies Announces Inclusion in the Euronext Tech Leaders Index
DBV Technologies has been included in the Euronext Tech Leaders index, effective June 22, 2026. This recognition underscores the company's growth and innovation in the biopharmaceutical sector, particularly in developing treatments for food allergies. CEO Daniel Tassé expressed optimism about the increased awareness and opportunities this inclusion brings for the company and its mission.
Read more →DBVTDBV Technologies intégrera l’Indice Euronext Tech Leaders
DBV Technologies has announced its integration into the Euronext Tech Leaders index, effective June 22, 2026. This index aims to showcase high-growth European tech companies to institutional investors. DBV's CEO expressed pride in this recognition, attributing it to their scientific approach and advancements in developing the VIASKIN® Peanut patch for treating peanut allergies.
Read more →DBVTDBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference
DBV Technologies has announced a revision in its participation at the Goldman Sachs 47th Annual Global Healthcare Conference, where management will engage in 1-on-1 investor meetings. However, CEO Daniel Tassé will not attend the fireside chat due to travel disruptions. The company continues to focus on developing treatments for food allergies using its proprietary VIASKIN® patch technology.
Read more →DBVTDBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026
DBV Technologies announced positive results from its Phase 3 VITESSE study of the VIASKIN Peanut Patch, demonstrating significant efficacy in children with peanut allergies and comorbid atopic conditions. The company will also preview its THRIVE study, aimed at infants aged 6-12 months. Both studies will be presented at the EAACI Congress 2026 in Istanbul.
Read more →DBVT▼ -5.6%on this newsshared move
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
DBV Technologies announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference, scheduled for June 9, 2026. CEO Daniel Tassé will engage in a fireside chat, highlighting the company's focus on developing treatments for food allergies using their proprietary VIASKIN® patch technology. The event will be accessible via a live webcast and archived replay.
Read more →DBVTDBV Technologies Announces the Results of its 2026 Combined General Meeting
DBV Technologies held its 2026 Combined General Meeting where shareholders approved all proposed resolutions. The meeting was chaired by Michel de Rosen, Chairman of the Board. DBV Technologies is advancing its proprietary VIASKIN patch technology aimed at treating food allergies through epicutaneous immunotherapy. The company is committed to improving care for individuals with food allergies.
Read more →DBVTDBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
DBV Technologies has announced the screening of the first participant in its THRIVE Phase 2 study, which evaluates the efficacy and safety of the VIASKIN® Peanut Patch for infants aged 6 to 12 months with peanut allergies. The study aims to assess the potential for ad lib consumption of dietary peanuts in this young population. This initiative is based on research suggesting that early interventions may positively influence allergy management and outcomes.
Read more →DBVTDBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq
DBV Technologies announced that CEO Daniel Tassé will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The event will take place at Nasdaq in New York, and a live webcast will be available for those interested. DBV Technologies is dedicated to developing treatments for food allergies using its proprietary VIASKIN technology.
Read more →DBVTDBV Technologies Reports First Quarter 2026 Financial Results
DBV Technologies reported its first-quarter financial results for 2026, showing a cash position of $229 million, which is expected to fund operations into the second quarter of 2027. The company is focused on the Biologics License Application (BLA) submissions for its VIASKIN® Peanut Patch targeted at children ages 4 to 7. Despite a rising net loss of $47.6 million compared to the previous year, DBV is moving forward with its comprehensive development plan for addressing food allergies. Additionally, the upcoming THRIVE Phase 2 study will assess the effectiveness of the patch in infants aged 6 to 12 months.
Read more →About DBV Technologies S.A.
Headquarters107 AVENUE DE LA REPUBLIQUE, CHATILLON, I0, 92320
BIOPHARMAWATCH ELITE PLUS
Trade the next DBVT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime